Biomedical research at Oslo University Hospital
Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.
Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.
Click here to see hierarchical division and subunit overview
Summary of publications:
Publications (original articles or review articles) published in 2017 from OUS - Molecular Genetic Studies of Breast and Ovarian Cancer
35 publications found
AKT1low Quiescent Cancer Cells Promote Solid Tumor Growth
Mol Cancer Ther, 17 (1), 254-263
DOI 10.1158/1535-7163.MCT-16-0868, PubMed 29054988
Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome
Breast Cancer Res, 19 (1), 44
DOI 10.1186/s13058-017-0812-y, PubMed 28356166
Widespread alternative exon usage in clinically distinct subtypes of Invasive Ductal Carcinoma
Sci Rep, 7 (1), 5568
DOI 10.1038/s41598-017-05537-0, PubMed 28717182
Interrogating open issues in cancer precision medicine with patient-derived xenografts
Nat Rev Cancer, 17 (4), 254-268
DOI 10.1038/nrc.2016.140, PubMed 28104906
Pan-cancer analysis of homozygous deletions in primary tumours uncovers rare tumour suppressors
Nat Commun, 8 (1), 1221
DOI 10.1038/s41467-017-01355-0, PubMed 29089486
A novel hypoxia response element regulates oxygen-related repression of tissue factor pathway inhibitor in the breast cancer cell line MCF-7
Thromb Res, 157, 111-116
DOI 10.1016/j.thromres.2017.07.013, PubMed 28734156
Data-driven analysis of immune infiltrate in a large cohort of breast cancer and its association with disease progression, ER activity, and genomic complexity
Oncotarget, 8 (34), 57121-57133
DOI 10.18632/oncotarget.19078, PubMed 28915659
HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures
Nat Med, 23 (4), 517-525
DOI 10.1038/nm.4292, PubMed 28288110
Whole-Genome Sequencing Reveals Breast Cancers with Mismatch Repair Deficiency
Cancer Res, 77 (18), 4755-4762
DOI 10.1158/0008-5472.CAN-17-1083, PubMed 28904067
Interactions between the tumor and the blood systemic response of breast cancer patients
PLoS Comput Biol, 13 (9), e1005680
DOI 10.1371/journal.pcbi.1005680, PubMed 28957325
Alcohol, Physical Activity, Smoking, and Breast Cancer Subtypes in a Large, Nested Case-Control Study from the Norwegian Breast Cancer Screening Program
Cancer Epidemiol Biomarkers Prev, 26 (12), 1736-1744
DOI 10.1158/1055-9965.EPI-17-0611, PubMed 28877889
Evaluation of metabolomic changes during neoadjuvant chemotherapy combined with bevacizumab in breast cancer using MR spectroscopy
Metabolomics, 13 (4), 37
DNA methylation signature (SAM40) identifies subgroups of the Luminal A breast cancer samples with distinct survival
Oncotarget, 8 (1), 1074-1082
DOI 10.18632/oncotarget.13718, PubMed 27911866
DNA methylation at enhancers identifies distinct breast cancer lineages
Nat Commun, 8 (1), 1379
DOI 10.1038/s41467-017-00510-x, PubMed 29123100
Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition
Cancer Discov, 7 (10), 1098-1115
DOI 10.1158/2159-8290.CD-17-0222, PubMed 28652380
A somatic-mutational process recurrently duplicates germline susceptibility loci and tissue-specific super-enhancers in breast cancers
Nat Genet, 49 (3), 341-348
DOI 10.1038/ng.3771, PubMed 28112740
Corrigendum: A somatic-mutational process recurrently duplicates germline susceptibility loci and tissue-specific super-enhancers in breast cancers
Nat Genet, 49 (11), 1661
DOI 10.1038/ng1117-1661a, PubMed 29074948
Body mass index and breast cancer survival: a Mendelian randomization analysis
Int J Epidemiol, 46 (6), 1814-1822
DOI 10.1093/ije/dyx131, PubMed 29232439
Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients
Breast Cancer Res, 19 (1), 125
DOI 10.1186/s13058-017-0916-4, PubMed 29183390
Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment response
Breast Cancer (Dove Med Press), 9, 185-198
DOI 10.2147/BCTT.S115600, PubMed 28356768
PHIP - a novel candidate breast cancer susceptibility locus on 6q14.1
Oncotarget, 8 (61), 102769-102782
DOI 10.18632/oncotarget.21800, PubMed 29262523
Somatic mutations reveal asymmetric cellular dynamics in the early human embryo
Nature, 543 (7647), 714-718
DOI 10.1038/nature21703, PubMed 28329761
Intrinsic subtypes and benefit from postmastectomy radiotherapy in node-positive premenopausal breast cancer patients who received adjuvant chemotherapy - results from two independent randomized trials
Acta Oncol, 57 (1), 38-43
DOI 10.1080/0284186X.2017.1401735, PubMed 29172851
Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice
Cancer Res, 77 (6), 1250-1260
DOI 10.1158/0008-5472.CAN-16-2179, PubMed 28254861
Association analysis identifies 65 new breast cancer risk loci
Nature, 551 (7678), 92-94
DOI 10.1038/nature24284, PubMed 29059683
Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up
Breast Cancer Res, 19 (1), 120
DOI 10.1186/s13058-017-0911-9, PubMed 29137653
Age, estrogen, and immune response in breast adenocarcinoma and adjacent normal tissue
Oncoimmunology, 6 (11), e1356142
DOI 10.1080/2162402X.2017.1356142, PubMed 29147603
Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate
ESMO Open, 2 (2), e000158
DOI 10.1136/esmoopen-2017-000158, PubMed 28761742
Breast Cancer Molecular Stratification: From Intrinsic Subtypes to Integrative Clusters
Am J Pathol, 187 (10), 2152-2162
DOI 10.1016/j.ajpath.2017.04.022, PubMed 28733194
Serum N-glycome alterations in breast cancer during multimodal treatment and follow-up
Mol Oncol, 11 (10), 1361-1379
DOI 10.1002/1878-0261.12105, PubMed 28657165
Assessment of TP53 Polymorphisms and MDM2 SNP309 in Premenopausal Breast Cancer Risk
Hum Mutat, 38 (3), 265-268
DOI 10.1002/humu.23154, PubMed 27957778
BRCA2 Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer
Cancer Res, 77 (11), 2789-2799
DOI 10.1158/0008-5472.CAN-16-2568, PubMed 28283652
TP53 Mutations in Breast and Ovarian Cancer
Cold Spring Harb Perspect Med, 7 (1)
DOI 10.1101/cshperspect.a026252, PubMed 27815305
The Longitudinal Transcriptional Response to Neoadjuvant Chemotherapy with and without Bevacizumab in Breast Cancer
Clin Cancer Res, 23 (16), 4662-4670
DOI 10.1158/1078-0432.CCR-17-0160, PubMed 28487444
Molecular signatures reflecting microenvironmental metabolism and chemotherapy-induced immunogenic cell death in colorectal liver metastases
Oncotarget, 8 (44), 76290-76304
DOI 10.18632/oncotarget.19350, PubMed 29100312